Is There an Ideal Dose of Intravenous Fentanyl in the Prehospital Setting

October 25, 2017 updated by: University of Aarhus

Is There an Ideal Dose of Intravenous Fentanyl in the Prehospital Setting: A Prospective Cluster-randomized Comparison of 2 vs. 3 μg/kg/Transport

In a previous study the investigators evaluated the apparent efficacy and safety of intravenous fentanyl administered by ambulance personnel and found that 58.4% (CI 56.4-60.4) out of 2348 prehospital patients treated with fentanyl still experienced moderate to severe pain [numeric rating scale (NRS, 0-10) > 3] at hospital arrival. The number of patients with possible fentanyl-related side effects was low.

Therefore, the aim of the present study is to explore the efficacy and safety of a liberalized pain treatment protocol for ambulance personnel (a total of 3 μg/kg per transport) compared with existing restrictive protocol (a total of 2 μg/kg per transport). The investigators hypothesize that:

  • A higher proportion of patients will experience sufficient pain relief at hospital admission (NRS < 4) using the liberalized protocol and
  • There will be no differences in the proportion of potential fentanyl related side-effects are observed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A prospective cluster-randomized trial observing proportional differences in sufficient pain relief at hospital admission (NRS < 4) and potential fentanyl related side-effects between patients treated by ambulance personnel applying either:

  • a more liberal treatment approach (a total of 3 μg/kg per transport) or
  • existing treatment approach (a total of 2 μg/kg per transport).

The Ambulance stations and their affiliated ambulance personnel are stratified into 5 clusters according to size/average transports per month and randomized to either liberal or existing treatment approach within each cluster. As patients are not randomized on an individual level baseline differences between the two groups and its patients are adjusted statistically with relevant confounders on 3 overall levels:

  1. Patients: Charlson Comorbidity Index Score, main overall diagnose category, inhospital surrogate measures of disease severity (intensive care unit admission and 30-day mortality).
  2. Ambulance personnel: Years of experience and preinterventional cumulative fentanyl administration and
  3. Ambulance stations and geographical factors: prehospital time measures and geographical distance from site of emergency to hospital.

These covariates are obtained from the Danish National Patient Registry, the Danish Civil Registration System and the electronic prehospital patient journal.

Study Type

Interventional

Enrollment (Actual)

7093

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 110 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with acute pain treated with intravenous fentanyl by ambulance personnel

Exclusion Criteria:

  • Reduced conscious level (GCS < 15) before initiation of fentanyl treatment
  • Reduced respiratory rate (< 10/minute) before initiation of fentanyl treatment
  • Patient weight < 30 kg
  • Known opioid allergy
  • Women in labour
  • Chronic pain conditions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Existing treatment
Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
Experimental: More liberal treatment
Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of patients with sufficient pain relief (NRS < 4) at hospital arrival
Time Frame: Up to 6 hours
Up to 6 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with reduced Glasgow Coma Scale (<15) after fentanyl administration and at any given point during transport
Time Frame: Up to 6 hours
Up to 6 hours
Proportion of patients with reduced respiratory rate (<10/minute) after fentanyl administration and at any given point during transport
Time Frame: Up to 6 hours
Up to 6 hours
Proportion of patients with reduced peripheral oxygen saturation (< 90%) after fentanyl administration and at any given point during transport
Time Frame: Up to 6 hours
Up to 6 hours
Proportion of patients with hypotension after fentanyl administration and at any given point during transport
Time Frame: Up to 6 hours
Hypotension defined as a drop in mean arterial pressure (MAP) >= 10 mmHg to a MAP < 70 mmHg
Up to 6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Hans Kirkegaard, Professor, Aarhus University Hospital
  • Principal Investigator: Kristian Friesgaard, MD, PhD Student, University of Aarhus
  • Study Chair: Lone Nikolajsen, DmSc, Aarhus University Hospital
  • Study Chair: Erika Frischknecht Christensen, Professor, Northern Denmark Region
  • Study Chair: Matthias Giebner, MD, Central Denmark Region
  • Study Chair: Claus-Henrik Rasmussen, MD, Central Denmark Region

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

October 1, 2017

Study Completion (Actual)

October 1, 2017

Study Registration Dates

First Submitted

September 12, 2016

First Submitted That Met QC Criteria

September 22, 2016

First Posted (Estimate)

September 26, 2016

Study Record Updates

Last Update Posted (Actual)

October 27, 2017

Last Update Submitted That Met QC Criteria

October 25, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe